Bank of Montreal Can decreased its stake in TherapeuticsMD Inc (NASDAQ:TXMD) by 1.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,488 shares of the company’s stock after selling 1,231 shares during the period. Bank of Montreal Can’s holdings in TherapeuticsMD were worth $388,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp raised its position in shares of TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock valued at $28,105,000 after buying an additional 253,237 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock valued at $298,000 after buying an additional 20,148 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock valued at $4,510,000 after buying an additional 60,229 shares in the last quarter. Geode Capital Management LLC raised its position in shares of TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock valued at $9,213,000 after buying an additional 117,660 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock valued at $70,574,000 after buying an additional 515,992 shares in the last quarter.

TherapeuticsMD Inc (TXMD) traded down 1.567% on Wednesday, hitting $5.906. 533,901 shares of the company’s stock were exchanged. TherapeuticsMD Inc has a 52-week low of $3.50 and a 52-week high of $8.30. The firm has a 50 day moving average price of $5.58 and a 200-day moving average price of $5.54. The stock’s market cap is $1.20 billion.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The company had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. During the same quarter last year, the company earned ($0.11) earnings per share. The firm’s revenue for the quarter was down 3.4% compared to the same quarter last year. Analysts predict that TherapeuticsMD Inc will post ($0.42) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.watchlistnews.com/therapeuticsmd-inc-txmd-shares-sold-by-bank-of-montreal-can/1532040.html.

Several brokerages recently issued reports on TXMD. Oppenheimer Holdings, Inc. set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Thursday, August 17th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research note on Monday, August 21st. Deutsche Bank AG set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Tuesday, August 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Tuesday, August 15th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, August 11th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. TherapeuticsMD currently has a consensus rating of “Buy” and an average price target of $16.14.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.